

Phases I and II studies

A phase IA safety study with 15 patients with exudative AMD(67), as well as a phase II study with 21 patients treated with pegaptanib associated or not to photodynamic treatment (PDT)(68), with a follow up of 3 months, have shown that the intravitreal administration of pegaptanib with 6 week intervals was well tolerated and had anatomic and visual benefits(69).

[View PDF](#)